NewTimeSpace News:As of 09:34 on February 6, 2026, the CSI Traditional Chinese Medicine (TCM) Index (930641) surged 1.90%. Among its constituent stocks, Panlong Pharmaceutical Co., Ltd. soared 10.01%, Longshen Rongfa Pharmaceutical Co., Ltd. climbed 9.21%, Xintian Pharmaceutical Co., Ltd. advanced 6.21%, while other stocks such as Hongri Pharmaceutical Co., Ltd. and Shanghai Kaibao Pharmaceutical Co., Ltd. followed suit. TheChina Universal CSI Chinese Medicine ETF (560080) opened higher and rose 2.16%, approaching a four-day winning streak, with the latest price at RMB 1.09. Over a longer time frame, as of February 5, 2026, the ETF had achieved a cumulative increase of 0.57% in the past week. (The stocks listed above are merely constituent stocks of the index and do not constitute specific investment recommendations.)

In terms of liquidity, theChina Universal CSI Chinese Medicine ETF recorded an intraday turnover rate of 3.23% and a trading volume of RMB 84.3488 million. Looking back, as of February 5, the ETF's average daily trading volume in the past week reached RMB 75.8619 million, ranking first among comparable funds.

Regarding scale, theChina Universal CSI Chinese Medicine ETF's size increased by RMB 46.8777 million in the past week, achieving significant growth, with the new scale ranking 1st out of 4 comparable funds. (Data source: Wind)

In terms of share count, the ETF's shares increased by 99.5 million units in the past two weeks, realizing remarkable growth, with the new share count ranking 2nd out of 4 comparable funds. (Data source: Wind)

For capital flow, theChina Universal CSI Chinese Medicine ETF recorded a latest net capital outflow of RMB 31.4544 million. Over the recent 10 trading days, it achieved net capital inflows on 7 days, accumulating a total of RMB 98.0131 million in "capital absorption" and an average daily net inflow of RMB 9.8013 million. (Data source: Wind)

Data shows that leveraged capital has been continuously deploying in the ETF. The latest margin purchase amount of theChina Universal CSI Chinese Medicine ETF reached RMB 13.9580 million, and the latest margin trading balance stood at RMB 57.9597 million. (Data source: Wind)

As of February 5, theChina Universal CSI Chinese Medicine ETF had a NAV increase of 9.50% in the past two years. In terms of profitability, as of February 5, 2026, since its establishment, the ETF has achieved a maximum monthly return of 16.46%, the longest consecutive monthly growth period of 5 months with a cumulative increase of 20.20%, and an average monthly return of 5.17% in upward months. As of February 5, 2026, the ETF's annualized excess return over the benchmark in the past two years was 2.47%, ranking among the top 2 out of 4 comparable funds.

Regarding drawdown, as of February 5, 2026, the ETF's maximum drawdown since the beginning of the year was 3.92%, with a relative benchmark drawdown of 0.05%, indicating a low drawdown risk among comparable funds.

In terms of fees, theChina Universal CSI Chinese Medicine ETF has a management fee rate of 0.50% and a custodian fee rate of 0.10%, the lowest among comparable funds.

For tracking accuracy, as of February 5, 2026, the ETF's tracking error since the beginning of the year was 0.006%, the highest tracking accuracy among comparable funds.

From a valuation perspective, the latest price-earnings ratio (PE-TTM) of the CSI TCM Index tracked by theChina Universal CSI Chinese Medicine ETF is only 24.6 times, at the 17.57% quantile of the past five years. This means the valuation is lower than 82.43% of the time in the past five years, standing at a historical low level.

TheChina Universal CSI Chinese Medicine ETF closely tracks the CSI TCM Index. This index selects listed company securities engaged in businesses such as TCM production and sales as samples to reflect the overall performance of listed companies related to the TCM concept.

Data shows that as of January 30, 2026, the top 10 weight stocks of the CSI TCM Index (930641) were Yunnan Baiyao Group Co., Ltd., Pien Tze Huang Pharmaceutical Co., Ltd., Dong'e Ejiao Co., Ltd., Tongrentang Co., Ltd., Jilin Aodong Pharmaceutical Group Co., Ltd., China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., Baiyunshan Pharmaceutical Holdings Company Limited, Yiling Pharmaceutical Co., Ltd., Zhongsheng Pharmaceutical Co., Ltd., and Darentang Pharmaceutical Co., Ltd., with a combined weight of 55.13%. (The stocks listed above are merely constituent stocks of the index and do not constitute specific investment recommendations.)

CGWS stated that according to news on the afternoon of February 5, eight ministries and commissions including the Ministry of Industry and Information Technology issued the "Implementation Plan for the High-Quality Development of the Traditional Chinese Medicine Industry (2026—2030)". It mentions that by 2030, a number of leading TCM industrial enterprises with prominent leading and driving capabilities will be cultivated, along with 60 high-standard TCM raw material production bases. It will promote the approval and listing of a number of innovative TCM drugs, newly cultivate 10 large proprietary Chinese medicine varieties, and facilitate the transformation of a number of TCM preparations from medical institutions into innovative TCM drugs.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.